<DOC>
	<DOCNO>NCT00599235</DOCNO>
	<brief_summary>Hypertension ( persistently elevate blood pressure ) major risk factor heart disease stroke . Hypertensive individual show reduce exercise capacity , present early stage contributes increase cardiovascular risk . Sildenafil belong class drug call phosphodiesterase type 5 ( PDE5 ) inhibitor , work enhance effect nitric oxide , substance dilates blood vessel increase blood flow . We hypothesize sildenafil , effect nitric oxide blood flow , improve exercise capacity hypertensive patient . Therefore , main aim study investigate effect PDE5 inhibition exercise capacity vascular function hypertension , compare effect hypertensive patient healthy control .</brief_summary>
	<brief_title>Sildenafil Exercise Capacity Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<mesh_term>Hydralazine</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<criteria>Male ( age range : 18 70 year ) Appropriate blood pressure range Hypertensive Systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg Controls Systolic BP &lt; 140 mmHg diastolic BP &lt; 90mmHg Written inform consent Female History coronary artery , cerebrovascular peripheral vascular disease within last 6 month Total cholesterol &gt; 6.5 mmol/L Current alcohol abuse Diabetes mellitus Asthma Taking antihypertensive , vasoactive endothelial function modify drug withdraw purpose study ECG evidence clinically significant arrhythmia cardiac ischaemia Clinically significant abnormality screen blood test Contraindication strenuous exercise Current involvement research project Other clinically relevant condition Lack write informed consent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Exercise capacity</keyword>
	<keyword>PDE5 inhibitor</keyword>
</DOC>